https://www.selleckchem.com/products/ng25.html
The purpose of this study was to employ dual tracers 16α-[18F]fluoro-17β-estradiol ( F-FES) and [18F]fluorodeoxyglucose ( F-FDG) as imaging biomarkers in predicting progression-free survival (PFS) in ER-positive metastatic breast cancer (MBC) patients receiving fulvestrant therapy. We retrospectively analyzed 35 HR+HER2- MBC patients who underwent F-FES and F-FDG PET/CT scans prior to fulvestrant therapy in our center. The SUVmax across all metastatic lesions on the PET/CT were assessed. The heterogeneity of ER expression was assigned by t
Gefällt mir
Kommentar
Teilen
